Cargando…
Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study
AIMS: To determine tolerability and the optimal dose regimen of the soluble guanylate cyclase stimulator vericiguat in patients with chronic heart failure and preserved ejection fraction (HFpEF). METHODS AND RESULTS: SOCRATES-PRESERVED was a prospective, randomized, placebo-controlled double-blind,...
Autores principales: | Pieske, Burkert, Maggioni, Aldo P., Lam, Carolyn S.P., Pieske-Kraigher, Elisabeth, Filippatos, Gerasimos, Butler, Javed, Ponikowski, Piotr, Shah, Sanjiv J., Solomon, Scott D., Scalise, Andrea-Viviana, Mueller, Katharina, Roessig, Lothar, Gheorghiade, Mihai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400074/ https://www.ncbi.nlm.nih.gov/pubmed/28369340 http://dx.doi.org/10.1093/eurheartj/ehw593 |
Ejemplares similares
-
Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial
por: Senni, Michele, et al.
Publicado: (2022) -
Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
por: Ruehs, Hauke, et al.
Publicado: (2021) -
The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction
por: Greene, Stephen J., et al.
Publicado: (2013) -
Evaluation of high‐sensitivity C‐reactive protein and uric acid in vericiguat‐treated patients with heart failure with reduced ejection fraction
por: Kramer, Frank, et al.
Publicado: (2020) -
Left atrial function and maximal exercise capacity in heart failure with preserved and mid‐range ejection fraction
por: Maffeis, Caterina, et al.
Publicado: (2020)